Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Renmin Hospital of Wuhan University
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- TTCI
- Last Updated
- 5 years ago
Overview
Brief Summary
This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.
Detailed Description
This clinical trial is set out to evaluate the followings: 1. the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; 2. to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and 3. to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.
Investigators
Ye Qingsong
Professor, Director
Renmin Hospital of Wuhan University
Eligibility Criteria
Inclusion Criteria
- •Aged 18-65 years;
- •Voluntarily participate in this clinical trial and sign off "informed consent form";
- •Diagnosed with severe pneumonia of COVID: respiratory distress, RR \>30 times / min; resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.
- •Chest imaging confirm COVID-19 featured lesions in lung.
Exclusion Criteria
- •Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;
- •Severe liver disease (e.g., Child Pugh score \>=C or AST\> 5 times of the upper limit);
- •Patients with known severe renal insufficiency (estimated glomerular filtration rate \<=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;
- •Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;
- •Female patients who have no sexual protection in the last 30 days prior to the screening assessment;
- •Pregnant or lactating women or women using estrogen contraception;
- •Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period;
- •Other conditions that the researchers consider not suitable for participating in this clinical trial.
Outcomes
Primary Outcomes
TTCI
Time Frame: 1-28 days
Time to Clinical Improvement
Secondary Outcomes
- SPO2(1-28 days)
- Lung lesion(1-28 days)
- Body temperature(1-28 days)
- Blood test(1-28 days)
- Side effects in the treatment group(1-28 days)
- Immune function(1-28 days)
- C-reactive protein (mg/L)(1-28 days)
- Time of SARS-CoV-2 clearance(1-28 days)
- RR(1-28 days)